MDM2 has the capacity to interact with more than 100 proteins and macromolecules and the list is continuously increasing. The explanation for how a protein of 491 aa (amino acids) is able to display ...

A large proportion of late-stage breast cancers that have spread to other parts of the body (metastatic breast cancers) are characterized by overexpression of the protein Mdm2. Lindsey Mayo and ...

The p53–Mdm2 system is key to tumor suppression. We have recently reported that p53 as well as Mdm2 are capable of supporting DNA replication fork progression. On the other hand, we found that Mdm2 is ...

Overexpression of MDM2 is described in many human cancers, including breast carcinoma. 1, 3, 8 Overexpression of MDM2 protein correlates with high grade and was found to be an independent negative ...

Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) ...

Ethnicity & Disease, Vol. 18, Supplement 2: Research Centers in Minority Institutions (RCMI): Current Science (Spring 2008), pp. 1-8 (8 pages) Introduction: Mdm2 inhibits p53 transactivation by ...

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML. Studying MDM2 inhibitors using Venetoclax (Venclexta) has led to unique responses in patients with ...

WATERTOWN, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel ...

Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...

A study has identified a possible second-line treatment for melanoma patients. A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, PhD, and Ann ...

WATERTOWN, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...